18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer (COLOPET1)
|ClinicalTrials.gov Identifier: NCT01636674|
Recruitment Status : Unknown
Verified July 2012 by Bodil Elisabeth Engelmann, Naestved Hospital.
Recruitment status was: Active, not recruiting
First Posted : July 10, 2012
Last Update Posted : July 10, 2012
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.
The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.
|Condition or disease||Intervention/treatment|
|Colon Cancer||Other: 18F-fluordeoxyglucose positron emission tomography/ computed tomography|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||66 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer|
|Study Start Date :||July 2009|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||March 2013|
Other: 18F-fluordeoxyglucose positron emission tomography/ computed tomography
- time to recurrence
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01636674
|Principal Investigator:||Bodil E Engelmann, MD||Naestved Hospital|